Clinical data demonstrating positive patient outcomes over a sustained period of time are essential for all medical treatments. More than thirty articles have been published reporting the safety and effectiveness of the iFuse Implant.1 The iFuse Implant is the only SI joint fusion device with multiple published results from a randomized controlled trial and the only one with clinical studies demonstrating that treatment improved pain, patient function, and quality of life.2 Click here for list of publish of published articles.
Research reported in Open Orthopaedics Journal, on 50 patients that underwent the SI joint fusion procedure with the iFuse Implant, found early and sustained positive outcomes. In this study, patients were contacted after surgery to assess SIJ pain, satisfaction and work status. The patients reported significant improvements in 7 out of 9 categories of daily living. Moreover, 82% of patients were satisfied 40 months after the surgery, and they said they would undergo the same surgery again. It's notable that "13 patients who were out of work were able to return to work.”1
Ask your doctor to learn more about these published clinical results. Additionally, SI-BONE continues to sponsor clinical studies of the iFuse Implant.
1 Polly DW, et al., Neurosurgery. 2015. — Dr. Polly is an investigator on a clinical research study sponsored by SI-BONE. He has no financial interest in SI-BONE. Research was funded by SI-BONE, Inc. A list of additional published studies is available at www.si-bone.com/ous/results
2 Duhon B, et al. Triangular Titanium Implants for Minimally Invasive Sacroiliac Joint Fusion: 2-Year Follow-Up from a Prospective Multicenter Trial. Int J Spine Surg. 2016;10:Article 13. * Paid consultant of and conducts clinical research for SI-BONE Inc.
3 Rudolf* et al., Sacroiliac joint arthrodesis-MIS technique with titanium implants: report of the first 50 patients and outcomes. Open Orthopaedics Journal. 2012,6:495-502. * Paid consultant of, conducts clinical research for, and has an ownership interest in SI-BONE, Inc.